97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-070399 | 22/6/2007 | 21/05/2007 | An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis | An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis | Active ulcerative colitis | Intervention name : Rebamipide INN of the intervention : Rebamipide Dosage And administration of the intervention : Intracolonial (enema) Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Intracolonial (enema) | Otsuka Pharmaceutical Co., Ltd. | NULL | complete | 16 | BOTH | 120 | Phase 2 | Japan | |
| 2 | NCT00463151 (ClinicalTrials.gov) | June 2007 | 19/4/2007 | An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis | An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis | Colitis, Ulcerative | Drug: rebamipide | Otsuka Pharmaceutical Co., Ltd. | NULL | Completed | 16 Years | N/A | Both | 120 | Phase 2 | Japan |